drugset
drugset / Trial / NCT06414798

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798 ↗

Phase 1 Completed 60 enrolled AbbVie
RandomizedParallel-groupTriple-blindBasic science

Summary

This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants

Timeline

Start
2024-05-13
Primary completion
2025-02-08
Completion
2025-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-1088 Unknown — Oral

Indications

No indication recorded.